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One Sentence Summary: 2,6-diaminopurine is an exclusive and efficient UGA readthrough activator. 
 
Abstract:  
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Nonsense mutations cause about ten percent of genetic disease cases, and no treatments are 
available for these patients. Nonsense mutations can be corrected by molecules with nonsense 
mutation readthrough activity. Recently, an extract of the mushroom Lepista inversa has shown 
high-efficiency correction of UGA and UAA nonsense mutations. One active constituent of this 
extract is 2,6-diaminopurine (DAP). With high efficiency, DAP exclusively corrects UGA 
nonsense mutations in various cell lines, in vivo in mouse models, and in patient cells. The 
mechanism of action of DAP is through interference with the activity of a tRNA-specific 2’-O-
methyltransferase (FTSJ1) that is responsible for Cm34 formation in tRNATrp. Low toxicity and 
high-efficiency UGA nonsense mutation correction make DAP a good candidate for the 
development of treatments for genetic diseases caused by nonsense mutations. 
 
Introduction 
 
Nonsense mutations cause about 10% of genetic disease cases [1]. The presence of a premature 
termination codon (PTC) on an mRNA often activates the mRNA surveillance mechanism called 
nonsense-mediated mRNA decay (NMD), involving the main NMD factors UPF1, UPF2, and 
UPF3X (also called UPF3b) [2,3,4,5,6]. NMD specifically degrades PTC-containing mRNAs, 
thus preventing the synthesis of potentially harmful or nonfunctional truncated proteins. 
However, a fraction of PTC-containing mRNAs escape from NMD leaving open the possibility 
to act on them to correct nonsense mutations [7]. As to date no treatments are available for 
patients with a genetic disease caused by a nonsense mutation. The identification of efficient 
nonsense mutation correctors is a major public health issue.  
At the translational level, PTC recognition is closely related to the mechanism of termination. 
When the ribosome reaches a stop codon, competition occurs at the A site of the ribosome 
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between near-cognate tRNAs and the release factors eRF1 and eRF3 in eukaryotes. The result of 
this competition is 99.9% release factor recruitment, making translation a high-fidelity process 
during gene expression [8]. To ensure codon translation by cognate tRNAs, these are subject to 
various posttranscriptional modifications (including methylation, pseudouridylation, deamination 
and diverse complex modifications especially at positions 34 and 37 of the anticodon) with 
consequences for genome decoding [9,10,11].  tRNA anticodon modifications, including 2’-O-
methylations, play a major role in efficient, error-free decoding of mRNA codons. Many 
enzymes involved in tRNA modifications have been clearly linked to human pathologies and 
diseases [12,13].   
PTC readthrough during translation involves incorporation, by the ribosome, of an amino acid at 
the PTC position, so as to complete synthesis of the peptide chain encoded by the open reading 
frame [14,15,16,17]. A full-length protein synthesized by PTC readthrough results in a difference 
of no more than one amino acid between the protein synthesized and the wild-type protein. The 
protein is functional if the amino acid incorporated at the PTC position is compatible with the 
function of the protein. Recently, PTC readthrough has been shown to occur in specific 
cytoplasmic bodies called readthrough-bodies, suggesting that a specific environment may favor 
PTC-readthrough [18]. 
Strategies aiming to correct nonsense mutations and rescue expression of PTC-containing genes 
include inhibition of NMD, associated or not with activation of PTC readthrough 
[14,15,18,19,20]. Several molecules have been shown to activate readthrough, including 
members of the aminoglycoside family, such as gentamicin and G418, and non-aminoglycosides, 
such as PTC124/ataluren/Translarna and RTC13/14 [21,22,23,24,25,26,27,28,29]. Some of the 
compounds used, such as G418 and amlexanox, can both inhibit NMD and activate readthrough 
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[19,30]. Unfortunately, most of these molecules are either toxic or promote only low-efficiency 
correction of nonsense mutations in human cells. To date, only PTC124/ataluren/Translarna has 
reached clinical phase II/III, for cystic fibrosis and Duchenne muscular dystrophy. As the results, 
albeit encouraging, were too limited to offer patients a significant benefit, the development of 
this molecule was terminated, at least for these two pathologies [31,32]. 
In a recent report, we describe a specific screening system for identifying compounds that 
efficiently correct nonsense mutations in human cells. It uses a firefly reporter gene carrying a 
nonsense mutation and an intron located more than 55 nucleotides downstream, making the 
corresponding mRNA subject to NMD [33]. This system, unlike other, previously described 
screening systems using PTC-containing reporter mRNAs immune to NMD, reproduces the fate 
of PTC-containing mRNAs in patient cells [21,33,34,35]. We have used it to show that an extract 
of the common mushroom Lepista inversa (H7) acts as a very efficient corrector of UGA and 
UAA nonsense mutations in human cells [33]. 
In the present study we have identified the active compounds responsible for the readthrough 
activity of H7 extract, one of them being 2,6-diaminopurine (DAP). DAP has been previously 
used for antileukemia treatment and has been injected into children without showing any signs of 
toxicity [36]. Other activities have been reported for DAP, such as antiviral activity [37,38,39] 
and inhibition of miRNA activity [40]. DAP is shown here to be an efficient and exclusive 
corrector of UGA nonsense mutations in immortalized human cells, in patient cells, and in vivo 
in a mouse model. At the molecular level, DAP inhibits Cm34 methylation of tRNATrp by 
tRNA:methyltransferase 1 (FTSJ1), the human homolog of yeast TRM7, which also catalyzes 
formation of Cm32 and Nm34 in some tRNAs, such as tRNAPhe and tRNATrp [41,42].   
Materials and Methods 
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Cell culture and treatment 
HeLa cells were grown in DMEM (Gibco) supplemented with 10% serum (Gibco) and 1% 
Zellshield. The cell lines Calu-6 and HCC827-GR6 (a generous gift from Pr. P.A. Jänne, Dana-
Farber Cancer Institute, Boston, MA, U.S.A.) [43] were grown in RPMI 1640 (Gibco) 
supplemented with 10% serum (Gibco) and 1% Zellshield. Cystic fibrosis patient cells were 
grown in BESM medium (Lonza Biosciences). 
Cell transfections were performed with lipofectamine 3000 (Life technologies) according to the 
supplier’s recommendations.  
 
Constructs 
Fluc-int-UGA has been described in [33]. Expression vectors for FTSJ1/TRM7 (pEZ-V1624-
M68-FTSJ1) and CTU1 (pEX-H4779-M02) were purchased from GeneCopoeia (Rockville, 
USA). 
 
Fractionation of Lepista inversa extract H7 
As previously described in Benhabiles et al. (2017), H7 extract was obtained from freeze-dried 
L. inversa mushrooms. These were crushed in a mortar and subjected to three successive 
extractions with methanol/water 50:50 v:v. Concentrating the H7 extract under reduced pressure 
(Rotavapor, Büchi) yielded fraction F87-1. Fraction F87-1 was solubilized in water and 
partitioned with organic solvents of increasing polarity (cyclohexane, methylene chloride, ethyl 
acetate, and butanol successively), yielding five fractions (F87-2 to F87-5). The residual 
aqueous phase was named F87-6 (Figure 1A). Fraction F87-5, a butanol phase of F87-1, was 
fractionated by semi-preparative HPLC on a C18 Eclipse XDB column (21.2 x 150 mm, 5 µm; 
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Agilent Technologies) coupled to a Diode Array Detector (Agilent Technologies 1260 Infinity 
instrument). The mobile phases were (A): 95% water (0.05% trifluoroacetic acid), 5% 
acetonitrile and (B): 5% water (0.05% TFA), 95% acetonitrile. Separation was carried out at a 
flow rate of 10 mL/min, with the following gradient: 100% A for 6 min, 100 to 50% A in 30 
min, 50 to 0% A in 2 min, 100% B for 2 min, 0 to 100% A in 2 min, and 100% A for 2 min. 
Compounds were detected at 210 nm and 254 nm. Nine fractions, numbered F7 to F15, were 
obtained (Figure 1A). From 40 mg of fraction F87-5, respectively 1.4 mg, 2.4 mg, and 1.6 mg of 
fractions F10 (Rt at 5.0 min), F13 (Rt at 7.0 min), and F15 (Rt at 9.5 min) were recovered. All 
organic solvents and reagents (acetonitrile, trifluoroacetic acid) were of HPLC grade purity (Ref. 
83639.320 and Ref. 153112E, VWR, France). Ultrapure water obtained with a MilliQ water 
system (Millipore) was used for HPLC. 
 
Structure analysis by NMR and mass spectrometry 
NMR spectra were recorded at 298K on either a 400 MHz Bruker Avance III HD or a 600 MHz 
Avance II spectrometer (Bruker Biospin). Clitocine and DAP samples were dissolved in D2O 
(Eurisotop, France) and placed in 5-mm Wilmad tubes (Eurisotop, France). 1H and 13C resonance 
assignments were carried out by means of a series of 1D 1H and 13C spectra and 2D 1H COSY, 
and 1H-13C HSQC and HMBC experiments.  
ESI mass spectra were recorded with a hybrid ESI-Qq-TOF instrument (API Q-Star Pulsar I; 
Applied Biosystems-Thermo Fisher Scientific) operating in the positive ion detection mode. 
NMR and mass spectra were analyzed and compared with those obtained with authentic samples 
of clitocine (Ref. A-7052, Azur Isotopes, France) and DAP (Ref. 247847, Sigma, France).  
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Preparation of S9 mix 
The S9 mix was composed of 5 mM glucose-6-phosphate (Ref. G7879, Batch No.SLBP253V, 
Sigma, France), 33.5 mM KCl (Ref. P3911, Batch No. SLBQ3328V, Sigma, France), 8 mM 
MgCl2 (Ref. M8266, Batch No. SLBK9099V, Sigma, France), 4 mM β -NADP (Ref. N5755, 
Batch No. SLBJ7935V, Sigma, France), and 100 mM NaH2PO4 (Ref. S3139, Batch No. 
BCBT3558, Sigma, France) in ultrapure water (Ref. BE51200, Batch No. BCBT3558, Lonza, 
France). Seventy-five microliters (75 µl) of human liver S9 fraction (Pooled Human Liver S9, 20 
mg/ml, Ref. 452961, BD, France) was then added to 1380 µl of this S9 mix. The solution was 
warmed for 15 minutes at 37°C in a thermostatted water bath. The final protein concentration 
was 1 mg/ml after addition of working solutions. 
 
Protein extraction 
Proteins were extracted from 2x106 cells in lysis buffer containing 5% SDS, 50 mM Tris-HCl pH 
7, 20 mM EDTA, and a protease inhibitor cocktail (HALT Protease Inhibitor Cocktail, Pierce-
Biotechnology, Rockford, IL, USA). Lysates were subjected to 30 pulses of sonication (Branson 
Digital Sonifier/amplitude 20%) before a 5-min centrifugation at 8000g.  
 
Western blotting 
The equivalent of 2.5x105 cells was subjected to 10% SDS-PAGE before transfer of the proteins 
to a nitrocellulose membrane. The membranes were incubated overnight at 4°C in the presence 
of a 1/200 dilution of anti-p53 antibody (DO1) (Santa Cruz Biotechnology, Dallas, TX, USA), or 
a 1/1000 dilution of anti-CBP80 (H-300) antibody (Santa Cruz Biotechnology, Dallas, TX, 
USA). After three washes of the membrane in TBS Tween, the membranes were exposed to a 
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solution of peroxidase-coupled secondary antibody for detection of mouse- or rabbit-raised 
antibody (Jackson ImmunoResearch, Suffolk, UK). Antibodies were then detected with Super 
Signal West Femto Maximum Sensitivity Substrate (Pierce-Biotechnology, Rockford, IL, USA). 
Quantifications were performed with QuantityOne software (Biorad). 
 
RT-PCR 
The RT-PCR procedure and the primers used in this study have been described previously [19]. 
 
Firefly luciferase assay 
Firefly luciferase assay was performed as described previously [33]. 
 
Micronucleus induction assay 
The assay was performed by CytoxLab (Evreux, France). Briefly, L5178 TK+/- mouse cells were 
exposed to three concentrations of DAP for 24 or 3 h, followed by a 24-h recovery period when 
the experiment was performed in the presence of Aroclor-induced rat liver S9 metabolizing mix 
(at 2% final concentration). As positive control, mitomycin C was used at 1 µg/ml in 
experiments without S9 mix and cyclophosphamide at 6 µg/ml in experiments with S9 mix. The 
nuclei were then stained with Giemsa before counting the micronuclei among 1000 
mononucleated cells. 
 
Treatment of cystic fibrosis patient cells to measure CFTR function 
Cell growth and treatment conditions have been described previously [33]. All cystic fibrosis 
patient cells used in this study were obtained under authorization of the local ethics committee 
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"Comité de Protection des Personnes Nord Ouest IV". Patients were informed about the study 
and provided written consent.   
 
 
Toxicity assay 
The toxicity assay was performed 24 h after starting cell treatment. Cell culture supernatant was 
centrifuged at 6000g for 10 min to pellet cells and cell debris. One-twentieth of the supernatant 
was then used to measure adenylate kinase activity according to the supplier’s protocol (Lonza 
Biosciences, Basel, Switzerland). 
 
In vivo assay 
To initiate tumor growth, six-week-old nude mice received subcutaneously 10 million cells 
suspended in PBS. Starting 24 h after injection, the mice were force-fed daily with 200 µl 
DMSO or DAP solution at 5mg/ml. Tumors were measured three times weekly for three weeks 
to determine the tumor volume by the following formula: l (mm)xL (mm)xL (mm). The tumors 
were then collected and a fraction was used for western blot analysis after protein extraction. 
 
 
tRNA modification analysis 
tRNAs were purified with RNAzol (MRC, Cincinnati, OH, USA) from HeLa cells exposed for 
24 h to DMSO or 25 µM DAP, according to the manufacturer’s protocol. The detailed protocol 
and a description of the RiboMethSeq assay are provided elsewhere [44]. 
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DAP affinity columns 
Two hundred milligrams of Epoxy-activated Sepharose 6B (GE Healthcare) was suspended in 
distilled water and washed with 80 ml distilled water and then divided into two samples. 
Coupling was performed by adding 100 µmol of DAP suspended in 10 N NaOH to the first 
sample and incubating for 16 h at 37°C under gentle stirring. The packing for the “empty 
column” was obtained by adding 1 ml of 10 N NaOH to the second sample and proceeding 
similarly. The columns were then washed with 10 N NaOH and the remaining active groups 
were blocked by incubating the columns with ethanolamine at pH 8 overnight at 37°C. The 
columns were further washed with three cycles of 0.1 M CH3COOK pH 4 containing 0.5 M 
NaCl, followed by 0.1 M Tris-HCl pH 8 containing 0.5 M NaCl. Each column was then 
incubated overnight at 4°C under gentle stirring with an amount of extract equivalent to 120 
million cells, in the presence of HALT Protease Inhibitor Cocktail (Pierce). The columns were 
then washed five times with a buffer containing 50 mM Tris-HCl pH 7.4, 300 mM NaCl, and 
0.05% NP40, before elution with 100 µl of 100 mM DAP dissolved in DMSO. 
 
Amino-acid identification assay 
Sixty million HEK293FT cells were transfected with 120 µg Fluc-int-UGA construct with CaCl2 
in HBSS buffer. After a 24-h incubation at 37°C under 5% CO2, the cells were exposed for 24 h 
to 25 µM DAP or to DMSO as negative control, before immunoprecipitation of firefly luciferase 
with anti-firefly luciferase antibody (EDM Millipore, Temecula, USA) according to the protocol 
described in [45]. The immunoprecipitate was subjected to 10% SDS-PAGE and then firefly 
luciferase was detected by Coomassie staining. The band at 64 kDa present in DAP-treated cells 
but not in cells exposed to DMSO was excised for in-gel digestion with chymotrypsin. NanoLC-
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MSMS analysis of the protein digest was performed on a UltiMate-3000 RSLCnano System 
coupled to a Q-Exactive instrument (Thermo Fisher Scientific). 
MS/MS data were interpreted with the Mascot search engine (version 2.4.0, Matrix Science, 
London, UK) installed on a local server. Searches were performed with a tolerance on mass 
measurement of 10 ppm for precursor ions and 0.02 Da for fragment ions, against a database 
built with Fluc sequences degenerated at Tyr109, recombinant trypsin, and a list of classical 
contaminants (138 entries). Cysteine carbamidomethylation, methionine oxidation, protein N-
terminal acetylation, and cysteine propionamidation were searched as variable modifications. Up 
to three missed chymotrypsin cleavages were allowed. 
 
DAP stability assay  
The assay was performed by C-Ris Pharma, Saint Malo, France. Briefly, DAP at 10 mM was 
diluted in S9 mix (to 300 µM final concentration) and acetonitrile extraction was performed 
either immediately (T0) or after a 4-h incubation at 37°C. The samples were then centrifuged and 
directly analyzed by LC-MS. The extraction efficiency was estimated at 97.2%. After extraction, 
the collected supernatants were directly injected into the HPLC for analysis. Analysis was 
performed by MS to allow detection of potential metabolite(s). 
 
Results  
 
DAP contributes to the nonsense-mutation-correcting activity of Lepista inversa extract. 
An extract (H7) prepared from the mushroom Lepista inversa (also called Paralepista flaccida) 
has recently been shown to exhibit high UAA and UGA readthrough activity [33]. To identify 
the compounds responsible for this activity, a semi-preparative High Performance Liquid 
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Chromatography (HPLC) fractionation protocol was used. Nine fractions (F7 to F15) were 
obtained (Fig. 1A) and tested for PTC-readthrough activity in a system using firefly luciferase 
mRNA carrying a PTC and subject to NMD (Fig. 1B and [33]). DMSO and G418 were used, as 
a negative and a positive control, respectively. As expected [33], G418 corrected the UGA more 
efficiently than the UAG nonsense mutation and only weakly corrected the UAA nonsense 
mutation. Firefly luciferase activity measurements showed that fractions F13 and F15 correct the 
UAA nonsense mutation while fractions F10, F13, and F15 correct the UGA nonsense mutation 
(Fig. 1C). The combined use of nuclear magnetic resonance (NMR) and mass spectrometry 
allowed identifying the major component in fractions F13 and F15 as clitocine ((2R,3R,4S,5R)-
2-[(6-amino-5-nitropyrimidin-4-yl)amino]-5-(hydroxymethyl)oxolane-3,4-diol) (76% and 47%, 
respectively), known as a potent readthrough molecule [24]. In fraction F10 another molecule, 
present at about 77%, was assigned to 2,6-diaminopurine (DAP) on the basis of the 1H NMR 
analysis, and mass fragmentation data, and showed exclusive readthrough of the UGA stop 
codon (Fig. 1C). To demonstrate that the UGA readthrough activity exhibited by fraction F10 
was due to DAP and not to another minor compound, commercial DAP (98% purity) was tested 
for PTC-readthrough activity and showed exclusive correction of the UGA nonsense mutation. 
This confirms that the readthrough activity of fraction F10 is related to the presence of DAP 
(Fig. 1C). Given the toxicity issues associated with clitocine [46], we decided to focus on DAP. 
The half-maximal effective concentration (EC50) of DAP was then determined on the firefly 
luciferase constructs, with increasing amounts of DAP or G418 (as a reference molecule) in the 
cell culture medium (Fig. 1D). DAP showed maximal efficacy at 100 µM, with an EC50 at about 
50 µM. Notably, at 6.25µM, it was 10 times as effective as 600µM G418, and at 100µM, it 
reached 200 times as effective as 600µM G418.  
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DAP corrects endogenous nonsense mutations in various cell lines 
To further assess its nonsense-mutation-correcting efficiency, DAP was added to the culture 
medium of cancer cell lines harboring an endogenous nonsense mutation in the TP53 gene [33]. 
After 24 hours of treatment, proteins were extracted from the cells and the p53 protein was 
assessed by western blotting (Fig. 2). As anticipated, p53 protein was not detected after DMSO 
mock treatment due to the presence of the PTC in p53 mRNA [33]. DAP treatment allowed 
dose-dependent synthesis of the p53 protein in Calu-6 cells (UGA nonsense mutation), but not in 
Caco-2 cells (UAG nonsense mutation) or Caov-3 cells (UAA nonsense mutation). This is 
consistent with the results in Fig. 1C and confirms that DAP exclusively corrects the UGA 
nonsense mutation. The p53 protein was detected after DAP treatment at concentrations as low 
as 1.56 µM, while it was barely detected upon treatment with 25 µM G418. This is consistent 
with the results of Fig. 1C, showing that DAP corrects the UGA nonsense mutation more 
efficiently than G418. 
Even if DAP promotes the synthesis of full-length proteins from UGA-nonsense-mutation-
containing mRNAs, it is necessary to ascertain that the readthrough protein is functional. Such 
evidence was first provided by the high luciferase activity observed after DAP treatment (Fig. 
1C, 1D), indicating that the enzyme is functional. Three additional assays were used to further 
demonstrate that DAP promotes the synthesis of functional full-length proteins from PTC-
containing mRNAs. The first assay involved measuring the transcriptional activity of the p53 
readthrough protein in Calu-6 cells. Cells were transfected with an expression vector carrying the 
cDNA encoding firefly luciferase under a promoter with two p53-responsive elements (Fig. 3A) 
[33]. Upon DMSO treatment, only a basal luciferase activity was detected, reflecting promoter 
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leakage (Fig. 3B). In the presence of increasing amounts of G418, the luciferase activity 
remained at the background level, indicating that G418 does not promote synthesis of a 
functional full-length p53 protein. In contrast, upon DAP treatment, the luciferase activity 
significantly increased, clearly demonstrating that the p53 readthrough protein synthesized upon 
DAP treatment in Calu-6 cells is functional. The second assay used a p53 target gene such as p21 
[47]. The level of p21 mRNA was monitored by quantitative RT-PCR in Calu-6 cells exposed to 
DMSO, G418, or DAP (Fig. 3C). It was found to increase significantly in cells exposed to DAP, 
but not in the presence of G418. This second assay thus confirmed that DAP promotes the 
synthesis of a functional p53 protein in Calu-6 cells, more efficiently than does G418. 
Finally, in a third assay, the functionality of a readthrough protein produced upon DAP treatment 
was evaluated on cystic fibrosis patient cells homozygotic for a UGA nonsense mutation in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene collected from three patients 
recruited from three French cystic fibrosis reference centers. The cells were incubated with 
DMSO, G418, or DAP followed by the measurement of the iodine flux through the cell 
membrane, which reflects the functionality of the CFTR (Fig. 3D) [33,48]. In all three patient 
cells, DAP promoted the most efficient iodine transport through the cell membrane.  
Overall, the results shown in Fig.1 and 3 indicate that in the four tested models, DAP activates 
readthrough of UGA nonsense mutations to promote synthesis of functional readthrough 
proteins. 
 
DAP does not inhibit NMD 
Correction of UGA nonsense mutations by DAP might result from combined effect of NMD 
inhibition and readthrough activity, as shown for other molecules [19,30], or from readthrough 
16 
 
activation only. To check if DAP inhibits NMD, the efficiency of NMD was monitored by 
measuring the level of p53 mRNA in the presence of DMSO, DAP, or G418 (Fig. 4A). Total 
RNA was purified from Calu-6 cells after 24 hours treatment. At both tested concentrations, 
DAP failed to significantly inhibit NMD, unlike G418, which showed 1.8 time fold increase in 
p53 mRNA. This is consistent with previous reports demonstrating that G418 can both inhibit 
NMD and activate readthrough [19,30]. The fact that DAP does not affect NMD is also 
consistent with the observation that no inhibition of NMD was previously detected upon 
treatment with the H7 extract [33].     
 
DAP shows low toxicity 
Although DAP-containing H7 extract does not appear to be toxic [33], the toxicity of DAP was 
assessed by measuring the adenylate kinase activity in the culture medium of HeLa cells treated 
with DMSO, DAP, or the apoptosis inducer staurosporine (STS) used as a positive control (Fig. 
4B). After 24 hours of treatment, the release of adenylate kinase activity was detected for the 
cells exposed to STS, but not for the cells exposed to increasing amounts of DAP. This indicates 
that DAP is not cytotoxic, at least under these experimental conditions. This conclusion was 
supported by a second toxicity assessment focusing on the putative impact of DAP on DNA 
integrity. Briefly, mouse L5178Y TK+/- cells were exposed to DMSO or DAP for 24 hours or 3 
hours followed by 24 hours recovery, in the absence or presence of Aroclor-induced rat liver S9 
fraction, so as to reproduce the metabolizing conditions prevailing in the liver. Cells with nucleus 
injury, and particularly those with small nuclei, were then counted, these features being 
indicative of DNA damage and hence of tested-compound genotoxicity  (Table 1). No significant 
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increase in the number of micronucleated cells was measured. Overall, these results demonstrate 
that DAP is not genotoxic. 
To complete the study on the putative DAP toxicity, we evaluated the consequences of DAP 
treatment on gene expression at the transcription and at the translation levels. First, in HeLa 
cells, we assessed the impact of DAP on the whole transcription profile, as compared with the 
treatment by DMSO. No more than 0.13% of the genes (i.e. 30 genes out of 22935 human genes 
analyzed) showed more than 4-fold up- or downregulation (adjusted p-value <0.05, |log2FC|>= 
2). More importantly, no pathway was found to be specifically upregulated by DAP (Table 2 and 
Fig. S1). This analysis suggested that DAP does not target any specific metabolic pathway and 
that the 0.13% gene variation measured could be a nonspecific response to an unusual 
component in the cell. Secondly, 2D differential gel electrophoresis (2D-DIGE) was performed 
on the whole proteomes of HeLa cells exposed to DMSO or DAP. No visible differences were 
observed between the two proteomes (Fig. S2). Altogether, these results unambiguously indicate 
that DAP does not interfere at the mRNA or protein level with the gene expression program of 
HeLa cells strengthening the absence of toxicity in human cells observed at the Fig. 4B.    
DAP corrects nonsense mutations in vivo 
Stability of DAP under simulated in vivo conditions was assessed in human liver S9 extract to 
mimic the liver environment [49]. After 4 hours incubation, DAP and its metabolites were 
extracted by acetonitrile and subjected to HPLC/mass spectrometry analysis. No DAP-derived 
metabolites were detected under these experimental conditions, and recovery of the molecule 
after incubation exceeded 80%, indicating that DAP is stable and suggesting that it should be 
stable in vivo as well, since the liver is the main site of drug degradation in the body (Fig. 5A). 
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Next, the in vivo capacity of DAP to correct UGA nonsense mutations was assessed in a mouse 
model. Four-week-old immunodeficient nude mice were injected with identical number of Calu-
6 cells carrying a UGA nonsense mutation in the TP53 gene or HCC-GR6 cells having a wild-
type TP53 gene but carrying different tumor-inducing mutations (a small deletion in the EGFR 
gene and an amplification of MET gene leading to the constitutive activation of both receptors) 
[43]. For three weeks, the mice were forced-fed every day with DMSO or DAP and tumor 
growth was monitored three times per week. We assumed that if DAP induces expression of a 
functional p53 protein in Calu-6 cells, these cells should divide more slowly and enter apoptosis 
as previously reported [24]. After three weeks of treatment, a significant difference was observed 
between Calu-6-cell-injected mice exposed to DMSO and ones exposed to DAP (Fig. 5B – left 
panel): DAP strongly impaired tumor growth as compared to DMSO. In contrast, when HCC-
GR6 cells were used to induce tumor formation, no significant difference in tumor growth 
between DAP- and DMSO-exposed mice was observed (Fig. 5B – right panel). This suggested 
that the slow-down tumor growth observed with Calu-6 cells is likely due to rescue of p53 
protein synthesis in these cells. Rescue of p53 synthesis was indeed found to occur in the tumors 
of DAP-treated mice, as assessed by western-blotting (Fig. 5C).  
Altogether, these results demonstrated that orally administered DAP rescues functional 
expression of genes carrying a UGA nonsense mutation in vivo.  
 
Molecular mechanism of DAP-driven UGA readthrough 
To elucidate the molecular mechanism underlying the DAP-promoted UGA readthrough, mass 
spectrometry was used to identify the amino acid incorporated at the PTC position into firefly 
luciferase synthesized from the Fluc-int-UGA construct. HEK293FT cells treated with 25µM 
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DAP were chosen for their high rate of transfection, crucial to generating enough readthrough 
protein to be analyzed by mass spectrometry. The luciferase protein was digested with 
chymotrypsin to generate a PTC-position-containing peptide compatible with mass spectrometry 
analysis. Using this approach, we found only one amino acid, tryptophan, incorporated at the 
PTC position in the peptide of interest (Fig. 6A). These results clearly demonstrated that DAP-
promoted UGA readthrough is mediated by tRNATrp, by non-Watson-Crick base-pairing A*C at 
the Wobble position. Human tRNATrp was shown to have suppressor functions [50], and plant 
tRNATrp (CmCA) was also known to promote UGA readthrough [51]. 
 
 
To ensure accurate recognition, tRNA is subject to numerous posttranscriptional nucleotide 
modifications, notably in the anticodon triplet at the wobble position N34. Among the enzymes 
modifying tRNAs liable to recognize a stop codon by extended wobbling, human FTSJ1 (TRM7 
in yeast) exclusively modifies tRNAs involved in UGA readthrough [12]. In addition to other 
tRNA targets, FTSJ1 methylates the cytosine at position 34 of tRNATrp. Inhibition of this 
modification increases the capacity of tRNATrp to recognize the UGA stop codon. To test the 
hypothesis that DAP interferes with the activity of FTSJ1, HeLa cells were co-transfected with 
the pFluc-int-UGA construct and with increasing amounts of an expression vector for either 
FTSJ1 or CTU1 (an uridine thiolase  targeting U34 in tRNAGln and tRNALys, probably affecting 
the recognition of UAA stop codon [52]). The transfected cells were then treated with increasing 
amounts of DAP (Fig. 6B). Overexpression of FTSJ1, but not of CTUI, was found to strongly 
reduce DAP-promoted readthrough. This suggests that DAP promotes UGA readthrough by 
targeting FTSJ1 activity.  
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To confirm that DAP indeed inhibits FTSJ1 activity, RiboMethSeq analysis was performed to 
detect modulation of tRNA 2’-O-methylations in the presence of DAP (Fig. 6B and S3). HeLa 
cells were incubated with DMSO or DAP before extraction of small RNAs, which include 
tRNAs. RiboMethSeq analysis of human tRNAs was then performed [44]. In the presence of 
DAP, the level of 2’-O-methylation was significantly lower for three tRNAs, including 2’-O-
methylation of tRNATrp at position 34 (Fig. 6C), while other known Nm positions were not 
affected (Fig. S3). Although the human targets of FTSJ1 remain poorly characterized, 
modification of Cm34 in tRNATrp has been attributed to FTSJ1 [41]. It is noteworthy that the 
second affected tRNA (tRNAGln) also showed reduced Cm32 methylation. This is consistent with 
DAP-dependent inhibition of FTSJ1 activity. The third hit was 2’-O-methylation of tRNASer at 
position Gm18, attributed to TARBP1 activity. Overall, the results of the RiboMethSeq assay and 
of FTSJ1 overexpression converge to suggest that DAP acts by inhibiting the action of FTSJ1 at 
certain 2’-O-methylation sites in human tRNAs. 
Whether DAP interacts with FTSJ1 was then investigated by DAP affinity chromatography. The 
column packing was produced by covalent attachment of DAP to activated epoxy Sepharose 
beads. The column was then exposed to HeLa cell extract followed by competitive elution of the 
bound proteins with excess of DAP. The eluate was analyzed by western blotting for the 
presence of various proteins, including FTSJ1. Out of all tested targets, FTSJ1 was the only 
protein to be specifically bound to the DAP affinity column and absent in eluate from a column 
packed with beads alone. These results indicate that DAP binds to FTSJ1 (Fig. 6D). 
   
Discussion  
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Nonsense mutations cause about ten percent of genetic diseases [1] through silencing of the 
mutant gene. To date, we lack highly efficient molecules capable of rescuing the expression of 
genes harboring a nonsense mutation. Here we have focused our study on H7 extract from the 
common mushroom Lepista inversa, recently shown to promote expression of genes carrying 
UGA or UAA nonsense mutations [33]. Two molecules responsible for the activity of H7 extract 
were identified, one of those is clitocine, previously shown to correct nonsense mutations more 
efficiently than G418 [24]. The mode of action of clitocine differs from that of other readthrough 
activator molecules such as aminoglycosides, shown to interact with the ribosome [53]. Clitocine 
is incorporated into the mRNA, where it replaces the adenosine base and facilitates stop codon 
recognition by some near-cognate tRNAs [24]. The second nonsense-mutation-correcting 
molecule found here in H7 extract is DAP. DAP corrects UGA nonsense mutations only; it is the 
first molecule showing correction of only one stop codon. The UGA stop codon is the most 
frequent termination codon, both physiological and premature [54]. Here, in four different 
assays, we show that DAP promotes the synthesis of functional proteins. DAP also corrects UGA 
nonsense mutations more efficiently than G418, even though it does not inhibit NMD. Some 
other molecules such as PTC124/ataluren/Translarna [21], like H7 extract [33], have been shown 
to promote PTC readthrough without affecting NMD. Remarkably, DAP does not appear to be 
toxic even at high concentrations. Lastly, it rescues the expression of genes carrying UGA 
nonsense mutations in vivo and can be orally administered.  
DAP mode of action appears original, since this molecule targets an enzyme responsible for the 
posttranscriptional modification of tRNAs. DAP inhibits the activity of FTSJ1 methyltransferase, 
thus reducing Cm34-methylation in the tRNATrp anticodon loop, and, in turn, increasing 
readthrough at UGA stop codons only. tRNA modifications  play essential roles in the fidelity of 
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codon recognition, and their absence leads to either inefficient translation or to miscoding 
through binding of near-cognate tRNA. The amino acid inserted at the UGA stop codon is 
exclusively tryptophan in our experiments, indicating that the near-cognate tRNATrp is 
responsible for the read-through and miscodes by forming a C34oA(+3) at the third position of the 
codon (Trp is in the same codon box than the UGA stop). It is known that tRNATrp is 2’-O-
methylated at position 34 by FTSJ1. Although there is not yet structural evidence, all the 
evidence points to a stabilization of a Watson-Crick pair at the third position mediated by the 
methylation leading to a Cm34=G(+3) Watson-Crick in the cognate complex). Consequently, the 
absence of methylation promotes recognition of the UGA stop codon by the near-cognate 
tRNATrp [55]. The enzymes responsible for tRNA modifications thus constitute a new set of 
putative targets for nonsense mutation correction, since their targeted inhibition should promote 
PTC-readthrough. In addition, as posttranscriptional tRNA modifiers show specificity for 
particular tRNAs, positions, and modifications, their targeting might be adjusted to allow precise 
correction of nonsense mutations. 
DAP is likely one of the most efficient UGA readthrough activators identified to date. Given its 
high efficacy and low toxicity, it seems more compatible with a therapeutic approach than 
previously reported molecules. Another advantage of DAP is its selectivity for the UGA stop 
codon, which should reduce the risk of potential side effects. 
Correctors of nonsense mutations constitute possible drug candidates for the treatment of genetic 
diseases caused by nonsense mutations. They may also find a place in personalized medicine, 
since they would be used for patients with a particular mutation rather than for all patients with 
the same pathology. Only a fraction of patients suffering from a wide range of diseases should 
benefit from stimulated readthrough therapy. The readthrough molecules identified so far are 
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either highly toxic (e.g. aminoglycosides and clitocine) or not effective enough to offer sufficient 
therapeutic benefits (e.g. ataluren) [32,56,57,58]. New molecules are being developed in order to 
address all these issues, such as a derivative of ataluren named PTC414, which has higher 
efficacy than ataluren [59], and new-generation aminoglycosides [25,60,61], designed to increase 
the efficiency of readthrough correction and decrease the long-term toxicity associated with the 
previous generation of aminoglycosides. One of these, named ELX-02, is currently being tested a 
phase 1B clinical trial for cystic fibrosis (http://www.eloxxpharma.com/pipeline/). 
In conclusion, several lines of evidence show that DAP is an excellent drug candidate for the 
treatment of genetic diseases caused by UGA nonsense mutations. Its correction efficiency is ten 
to two hundred times that of G418, suggesting that it could have therapeutic benefits. The results 
obtained on cystic fibrosis patient cells and in vivo in a mouse model show that DAP can rescue 
the function of proteins synthesized from a gene carrying a nonsense mutation. In addition, it has 
been found to show low toxicity in cell cultures and no detectable toxicity in a mouse model. For 
all these reasons, DAP may someday offer new hope to patients whose pathology is caused by a 
UGA nonsense mutation. 
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Figure Legends 
Fig. 1. Identification of DAP as an efficient and exclusive corrector of UGA nonsense mutations. 
(A) Fractionation pathway of H7 L. inversa extract starting from fraction F87-1. (B) 
Schematic representation of the firefly luciferase construct used to measure readthrough 
activity. HeLa cells were transfected with an expression vector carrying a firefly 
luciferase (Fluc) gene consisting of the open reading frame encoding firefly luciferase 
interrupted by an intron and a nonsense codon at position 109. (C) Luciferase activity in 
HeLa cells transfected with the construct described in (B) carrying a UGA, UAA, or 
UAG PTC and incubated with DMSO, H7 extract, one of various H7 fractions, or DAP. 
the value of each luciferase measurement is presented on the table on the right side of the 
graph. (D) Readthrough activity on the construct described in (B) as a function of the 
G418 or DAP dose. Error bars represent SD. All data shown in Figures 1-C and -D are 
representative of two independent experiments. 
 
Fig. 2. DAP restores the synthesis of the endogenous TP53 gene carrying a UGA nonsense 
mutation but not if it carries a UAA or UAG nonsense mutation. Calu-6 (top), Caov-3 
(middle), and Caco-2 (bottom) cells were incubated with increasing amounts of DAP or 
G418 before purifying proteins and monitoring the level of p53 protein by western 
blotting. The molecular weight is indicated on the left side of each gel. Results are 
representative of two independent experiments. 
 
Fig. 3. DAP restores the function of p53 in Calu-6 cells. (A) Schematic representation of the 
construct used to measure the function of p53. The construct carries a cDNA encoding 
the firefly luciferase under a promoter having two p53-responsive elements (underlined). 
The arrow indicates the transcription start. (B) Luciferase activity in Calu-6 cells 
transfected with the construct described in (A) and treated with DMSO, DAP, or G418. 
The luciferase activity depends on the amount of functional p53 protein. (C) Level of p21 
mRNA measured by quantitative RT-PCR in Calu-6 cells treated with DMSO, DAP, or 
G418. The level of p21 mRNA is related to the amount of functional p53 protein 
synthesized in the cell. (D) DAP restores the function of CFTR in cystic fibrosis patient 
cells carrying a nonsense mutation on both CFTR alleles. Nose epithelial cells from three 
unrelated cystic fibrosis patients were incubated with the fluorescent molecule SPQ and 
with DMSO, G418 at 600µM, or DAP at 25µM before measuring the fluorescence, 
whose intensity correlates with the presence of functional CFTR at the cell membrane. 
The results presented in panels B and C are representative of at least two independent 
experiments. Error bar= S.D., p=Test-student. 
 
Fig. 4. DAP is not an NMD inhibitor and is not toxic. (A) Ratio of the level of p53 mRNA to that 
of GAPDH mRNA, as measured by RT-PCR, in Calu-6 cells treated with DMSO, DAP, 
or G418. The ratio calculated for DMSO treatment is arbitrarily set at 1. (B) Adenylate 
kinase activity in the culture medium of HeLa cells treated with DMSO (0), increasing 
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amounts of DAP, or the apoptosis inductor staurosporine (STS). The results presented in 
Figure 4 are representative of two independent experiments. Error bar= S.D., p=Test-
student. 
 
 
 
Fig. 5. DAP corrects UGA nonsense mutations in vivo. (A) Chromatograms illustrating the 
stability of DAP after 4 hours of incubation in S9 mix (in duplicate, two upper panels) as 
compared to the amount of DAP extracted at T0 (in duplicate, two lower panels). (B) 28 
nude mice were injected with Calu-6 or HCC-GR6 cells to promote tumor development. 
The mice were exposed to DMSO or DAP for about three weeks and tumor size was 
measured three times weekly and plotted on the graph. For each experimental condition, 
7 mice were used. (C) Western blot analysis of p53 protein in the Calu-6-cell tumors of 
the seven DMSO-exposed and seven DAP-exposed mice. GAPDH was used as loading 
control. The results presented in Figure 5 are representative of two independent 
experiments. Error bar= S.D., p=Test-student. 
 
Fig. 6. DAP interferes with the activity of FTSJ1. (A) Determination by mass spectrometry 
(MS/MS spectrum) of the amino acid incorporated at the PTC position. Firefly luciferase 
from HEK293FT cells transfected with the Fluc-int-UGA construct was 
immunoprecipitated and the identity of the amino acid incorporated at the PTC position 
was determined by mass spectrometry. The one-letter amino-acid sequence of Firefly 
luciferase is indicated on the top of the graph with the presence of the tryptophan (W) at 
the PTC position (B) Left panel: The efficiency of UGA readthrough by DAP decreases 
with increasing amounts of FTSJ1 but not with increasing amounts of CTU1. 
Readthrough efficiency was determined by measuring luciferase activity in HeLa cells 
co-transfected with the firefly luciferase construct described in Figure 1B and either with 
increasing amounts an expression vector for FTSJ1 or CTU10 (5, 1, or 2 µg). The empty 
expression vector (E.v.) was used as control. The cells were then exposed to 0, 0.39, 0.78, 
1.56, 6.25, 25, 100, 300, or 600 µM DAP for 24 hours before measuring the luciferase 
activity. The experiment was performed twice and the results of both experiments (Exp1 
and Exp2) are shown. Right panel: Western blot analysis of FTSJ1 and CTU1. (C) 2’-O-
methylation analysis of tRNATrp, tRNASER, and tRNAGLN by RiboMethSeq. A MethScore 
was attributed to each tRNA 2’-O-methylation for tRNA purified from HeLa cells treated 
with DAP (dark green histogram) or DMSO (light green histogram). The result of three 
independent experiments is indicated with the symbols nl►. (D) Analysis of DAP 
affinity column eluates shows that DAP interacts with FTSJ1. HeLa-cell extract was 
incubated with DAP covalently bound to beads or with beads alone. Proteins bound to the 
columns were eluted with excess DAP and the eluates analyzed by western blotting. Error 
bar= S.D., p=Test-student. 
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Table 1. Micronucleus induction assay. L5178Y TK+/- mouse lymphoma cells were exposed to 
increasing doses of DAP (as indicated), DMSO (DAP concentration 0 µM), or mitomycin 
or cyclophosphamide used as positive controls. 1000 cells were analyzed per condition 
and the number of micronucleated cells is reported. The experiment was performed in the 
absence (above) or presence (below) of S9 mix. 
Table 2. Impact of DAP on the HeLa-cell transcription profile. The 20 genes showing more than 
four-fold overexpression (upper table) and the 10 genes showing more than four-fold 
down-regulation (lower table) in the presence of DAP are listed. Gene names, gene 
identifications (gene ID), log2fold changes, and p-values are indicated. Some information 
about the function of the gene is added in the last column. 
 
 
Supplementary Materials 
 
Materials and Methods 
 
Transcriptomic analysis 
Ten million HeLa cells were exposed to DMSO or DAP for 24 h. Total RNA was extracted with 
RNazol reagent. Libraries were prepared by poly(A) enrichment with a PolyA Spin mRNA 
Isolation Kit (Biolabs) and strand-specific cDNA libraries were prepared with the Illumina 
Truseq Stranded mRNA Sample Preparation Kit (Illumina Inc., USA).	Reads were sequenced on 
an Illumina HiSeq 2500 device which produced six libraries of paired-end 100-nt long reads for 
three biological replicates of the two conditions. Reads were mapped with BWA-MEM (version 
0.7.12-r1039, http://bio-bwa.sourceforge.net/) against the human genome (GRCh37.p13). Reads 
having passed the default Illumina filter procedure (chastity filter) were counted on human genes 
with featureCounts (version 1.5.1, http://subread.sourceforge.net/). Condition clustering was 
checked by principal component analysis with R package FactoMineR (version 1.36). 
Differential expression analysis was performed on the raw read counts with R package DESeq2 
(version 1.14.1) [62]. Differentially expressed genes were determined with an adjusted p-value 
>0.05 and a |log2FC| >2. Heatmap representation of global gene expression of each library have 
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been produced using the normalized read counts (varianceStabilizingTransformation function of 
DESeq2) with R function heatmap.2 from R package gplots (version 3.0.1).  
 
Two-dimensional differential gel electrophoresis  
2D-DIGE was performed on a mixture of protein samples labeled according to the CyDye 
minimal labeling method (GE Healthcare). Control, H7, and DA extracts were respectively 
labeled respectively with Cy2, Cy3, and Cy5 and pooled. Finally, 5.4 µL Destreak Reagent (GE 
Healthcare), 1% (v/v) IPG buffer pH 3 −  11NL (GE Healthcare) and CHAPS lysis buffer were 
added to reach a final volume of 450 µl. Migration in the first dimension, i.e. isoelectric focusing 
(IEF), was carried out with IPG strips pH 3 −  11NL, 18 cm (GE Healthcare), after overnight 
passive rehydration. IEF was carried out on an Ettan IPGphor 3 IEF unit (GE Healthcare) with 
the following parameters: (1) constant voltage of 150 V for 3 h, (2) constant voltage of 300 V for 
3 h, (3) gradient from 300 V to 1000 V for 6 h, (4) gradient from 1000 V to 10000 V for 1 h, and 
(5) constant voltage of 10000 V for 2 h. The temperature was set at 20°C and the current was 
limited to 50 µA/strip. After the first dimension, the strips were equilibrated for 15 min in 
equilibration buffer containing 50 mM Tris-HCl pH 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) 
SDS, 0.02% Bromophenol Blue supplemented with 1% (w/v) DTT and subsequently for 15 min 
in equilibration buffer supplemented with 2.5% (w/v) iodoacetamide. The strips were rinsed in 
cathode buffer, placed on top of the second-dimension gel, and sealed with low-melt agarose. 
Cathode and anode buffers were added in the electrophoresis tank (Ettan DALT six, GE 
Healthcare) and the gels were run at 20°C. The migration settings were: (1) 5 mA for 2 h and (2) 
25 mA until the sample reached the end of the gel. Gels were scanned with a Typhoon FLA 9500 
(GE Healthcare). 
31 
 
Figure Legends 
 
Fig. S1. DAP does not interfere with the global cell transcription profile. (A) Heatmap 
representation of up- and down-regulated genes to show a low effect of the DAP on HeLa 
cells from three independent experiments. 3228 shown genes (adjusted p-value < 0,05) 
are represented by the normalized read counts with a log2 scale (see Supplementary 
Material). Dendrograms show the separation of control (DMSO1-3) VS DAP (DAP 1-3) 
treated libraries without clear pattern of dysregulation between samples. (B) Raw data for 
the transcriptomic analysis performed in triplicate on HeLa cells exposed to DMSO or 
DAP. 
 
 
Fig. S2. 2D-DIGE analysis. Extracts of HeLa cells exposed to DMSO (T) or DAP (DAP) were 
loaded for 2D-DIGE. Cy2 was used to detect proteins from cells exposed to DMSO and 
Cy5 was used to detect proteins from cells exposed to DAP. 
 
 
Fig. S3. Influence of DAP on tRNA modifications: 2’-O-methylation analysis of tRNAs by 
RiboMethSeq. A MethScore was attributed to each tRNA 2’-O-methylation in tRNA 
purified from HeLa cells treated with DAP (dark green histogram) or DMSO (light green 
histogram). 
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Table 1
Treatment
conditions
DAP dose (µM) Micronucleated
cells
Assay
without S9 
mix
20
40
40
70
Assay with
S9 mix
290
580
0 0
2
1
3
Mitomycin
(1 µg/ml)
100
0 0
0
1
0
Cyclophosphamide
(6 µg/ml)
60
Gene Name
S100A5
CMYA5
DCHS1
LRIT3
STC2
GRK7
IL18BP
ITGA10
ACRC
TRIB3
ASNS
ZNF721
PNLDC1
NUP210L
ZNF460
ANKRD11
SPEN
SESN2
CNTF
ADAM32
GeneID
6276
202333
8642
345193
8614
131890
10068
8515
93953
57761
440
170960
154197
91181
10794
29123
23013
83667
1270
203102
log2FoldChange
6.119
3.442
3.427
3.040
2.836
2.771
2.635
2.458
2.441
2.430
2.217
2.216
2.206
2.200
2.196
2.186
2.164
2.158
2.096
2.049
p‐value
3.080E‐68
1.899E‐33
9.008E‐18
1.221E‐13
7.358E‐64
4.546E‐12
2.408E‐12
2.317E‐09
1.663E‐19
1.419E‐28
5.830E‐79
1.117E‐26
6.267E‐11
8.162E‐08
5.326E‐10
4.476E‐58
2.006E‐92
2.522E‐19
1.291E‐07
4.829E‐07
Gene function
S100 family member involved in Ca2+ intracellular regulation
Anchor protein of PKA
Cadherin family member
Immunoglobulin‐like protein
Secreted protein putatively involved in Ca and phosphate transport
Retina‐specific kinase
inhibitor of the proinflammatory cytokine IL18
integrin involved in cell adhesion
putative nuclear protein
putative protein kinase induced by the transcription factor NF‐kappaB
Asparagine synthetase
putative transcriptional regulator
PARN Like, Ribonuclease Domain Containing 1
nucleoporin 210 like
Zinc finger protein
protein interacting with histone deacetylases
hormone inducible transcriptional repressor
member of the sestrin family of PA26‐related proteins
neurotrophic factor
member of the disintegrin family
List of the 20 genes showing at least 4‐fold upregulation in the presence of DAP
List of the 10 genes showing at least 4‐fold downregulation in the presence of DAP
Gene Name
COX2
COX3
ND6
COX1
SYNC
HSD17B8
ATP8
OLR1
INSL4
IDH2
GeneID
4513
4514
4541
4512
81493
7923
4509
4973
3641
3418
log2FoldChange
‐3.516
‐3.286
‐2.779
‐2.516
‐2.233
‐2.144
‐2.113
‐2.065
‐2.029
‐2.015
p‐value
1.361E‐102
4.176E‐86
2.717E‐36
2.860E‐36
3.857E‐10
4.807E‐10
5.218E‐19
1.925E‐30
9.034E‐21
4.480E‐09
Gene function
protein involved in the synthesis of prostaglandins
COX‐3 is an enzyme encoded by the PTGS1 gene
This protein is not functional in humans
subunit of the respiratory chain Complex I
Cytochrome c oxidase subunit I
member of the intermediate filament family
Estradiol 17 beta‐dehydrogenase 8
mitochondrial ATP synthase Fo subunit 8
Oxidized low‐density lipoprotein receptor 1
insulin‐like 4 protein Isocitrate dehydrogenase
Table 2
Supplemental Figure S1
DMSO 1
DMSO 2
DMSO 3
DAP 3
DAP 2
DAP 1
A
B
see attached file for Raw data
Supplemental Figure S2
Cy2 : T‐ Cy5 : DAP Merge
Cy5:DA 
Supplemental Figure S3
